FDA warns Mihon Corp./Boulla that VitalityXtra, PeakMax, ZapMax and ZoomMax supplements contain hidden sildenafil and diclofenac and are unapproved, misbranded drugs.
What happened
FDA reviewed the company’s website from August to December 2024 and Amazon storefronts in October 2024, and it obtained samples of the four products. Laboratory analyses found undeclared sildenafil in VitalityXtra, PeakMax, ZapMax and ZoomMax, and undeclared diclofenac in PeakMax, ZapMax and ZoomMax. The products are marketed as dietary supplements.
What FDA found
The products are unapproved new drugs because they are intended to affect the body and contain sildenafil and/or diclofenac without an FDA-approved drug application.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The labels do not disclose that the products contain sildenafil or diclofenac, making the labeling false or misleading.
FD&C Act section 502(a), 21 U.S.C. 352(a), and section 201(n), 21 U.S.C. 321(n)The labels lack adequate directions for use for prescription drugs that require a licensed practitioner’s supervision.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)The labels lack adequate warnings about the hidden drug ingredients and their serious risks.
FD&C Act section 502(f)(2), 21 U.S.C. 352(f)(2)The products cannot be dietary supplements because sildenafil and diclofenac were approved as drugs before being marketed as supplements or foods.
FD&C Act section 201(ff)(3)(B)(i), 21 U.S.C. 321(ff)(3)(B)(i)
What FDA wants
Within 15 working days, notify FDA in writing of the specific steps taken to correct the violations and prevent recurrence, include related documentation, or explain why correction cannot be completed and when it will be done.
Who should pay attention
- online sellers of male-enhancement supplements
- distributors and marketplaces listing supplement products
- consumers who take nitrates or NSAIDs
This is a summary. Read the original letter on fda.gov.